Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/functional-expression-of-trail-by-lymphoid-and-myeloid-tumour-cells-YO1ED2Slqy
References (34)
-
M. Hahne, D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. French, P. Schneider, Thierry Bornand, A. Fontana, D. Liénard, J. Cerottini, J. Tschopp (1996)
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 274
-
S. Marsters, R. Pitti, C. Donahue, S. Ruppert, K. Bauer, A. Ashkenazi (1996)
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmACurrent Biology, 6
-
P. Golstein (1997)
Cell death: TRAIL and its receptors.Current biology : CB, 7 12
-
P. Walker, P. Saas, P. Dietrich (1997)
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.Journal of immunology, 158 10
-
S. Nagata (1996)
Fas ligand and immune evasionNature Medicine, 2
-
T. Suda, H. Hashimoto, Masato Tanaka, T. Ochi, S. Nagata (1997)
Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the KillingThe Journal of Experimental Medicine, 186
-
S. Wiley, K. Schooley, P. Smolak, W. Din, Changwei Huang, J. Nicholl, G. Sutherland, T. Smith, C. Rauch, Craig Smith, R. Goodwin (1995)
Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity, 3 6
-
J. O'Connell, G. O'sullivan, J. Collins, F. Shanahan (1996)
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligandThe Journal of Experimental Medicine, 184
-
H. Walczak, M. Degli-Esposti, Richard Johnson, P. Smolak, Jennifer Waugh, N. Boiani, Martin Timour, M. Gerhart, K. Schooley, Craig Smith, R. Goodwin, C. Rauch (1997)
TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAILThe EMBO Journal, 16
-
M. Degli-Esposti, P. Smolak, H. Walczak, Jennifer Waugh, Changwei Huang, R. Dubose, R. Goodwin, Craig Smith (1997)
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor FamilyThe Journal of Experimental Medicine, 186
-
K. Clodi, Zahra Asgary, Shourong Zhao, K. Kliche, F. Cabanillas, M. Andreeff, A. Younes (1998)
Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cellsBritish Journal of Haematology, 103
-
S. Nagata, T. Suda (1995)
Fas and Fas ligand: lpr and gld mutations.Immunology today, 16 1
-
J. Drappa, A. Vaishnaw, K. Sullivan, J. Chu, K. Elkon (1996)
Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.The New England journal of medicine, 335 22
-
T. Gura (1997)
How TRAIL Kills Cancer Cells, But Not Normal CellsScience, 277
-
Tomohiro Takahashi, Masato Tanaka, C. Brannan, N. Jenkins, N. Copeland, T. Suda, S. Nagata (1994)
Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligandCell, 76
-
S. Marsters, J. Sheridan, R. Pitti, A. Huang, M. Skubatch, Daryl Baldwin, Yuan Jean, A. Gurney, A. Goddard, P. Godowski, A. Ashkenazi (1997)
A novel receptor for Apo2L/TRAIL contains a truncated death domainCurrent Biology, 7
-
H. Walczak, Robert Miller, K. Ariail, B. Gliniak, T. Griffith, M. Kubin, Wilson Chin, Jon Jones, A. Woodward, Tiep Le, Craig Smith, P. Smolak, R. Goodwin, C. Rauch, J. Schuh, D. Lynch (1999)
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 5
-
J. Sheridan, S. Marsters, R. Pitti, A. Gurney, M. Skubatch, Daryl Baldwin, Lakshmi Ramakrishnan, C. Gray, K. Baker, W. Wood, A. Goddard, P. Godowski, A. Ashkenazi (1997)
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.Science, 277 5327
-
F. Rieux-Laucat, F. Deist, C. Hivroz, I. Roberts, K. Debatin, A. Fischer, J. Villartay (1995)
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.Science, 268 5215
-
T. Griffith, D. Lynch (1998)
TRAIL: a molecule with multiple receptors and control mechanisms.Current opinion in immunology, 10 5
-
G. Pan, K. O’Rourke, A. Chinnaiyan, R. Gentz, R. Ebner, Jian Ni, V. Dixit (1997)
The Receptor for the Cytotoxic Ligand TRAIL, 276
-
N. Skelton, C. Quan, D. Reilly, H. Lowman (1999)
Structure of a CXC chemokine-receptor fragment in complex with interleukin-8.Structure, 7 2
-
A. Younes, V. Snell, U. Consoli, K. Clodi, Shourong Zhao, J. Palmer, E. Thomas, R. Armitage, M. Andreeff (1998)
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 100
-
S. Nagata, P. Golstein (1995)
The Fas death factorScience, 267
-
S. Nagata (1997)
Apoptosis by Death FactorCell, 88
-
I. Jeremias, I. Herr, T. Boehler, K. Debatin (1998)
TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cellsEuropean Journal of Immunology, 28
-
D. Kägi, F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hengartner, P. Golstein (1994)
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.Science, 265 5171
-
A. Younes, S. Zhao, D. Jendiroba, H. Kleine, F. Cabanillas, M. Andreeff (1995)
Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.Blood, 85 10
-
G. Pan, Jian Ni, Ying-Fei Wei, Guo-liang Yu, Reiner Gentz, V. Dixit (1997)
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.Science, 277 5327
-
M. Degli-Esposti, W. Dougall, P. Smolak, Jennifer Waugh, Craig Smith, R. Goodwin (1997)
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.Immunity, 7 6
-
Alessandra Bettinardi, D. Brugnoni, Eugenia Quiròs-Roldan, Alberto Malagoli, Stefania Grutta, Antonio Correra, Luigi Notarangelo (1997)
Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.Blood, 89 3
-
V. Snell, K. Clodi, Shourong Zhao, R. Goodwin, E. Thomas, S. Morris, M. Kadin, F. Cabanillas, M. Andreeff, A. Younes (1997)
Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignanciesBritish Journal of Haematology, 99
-
Richard Lee, J. Spielman, Dong Zhao, Kristin Olsen, E. Podack (1996)
Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.Journal of immunology, 157 5
-
R. Pitti, S. Marsters, S. Ruppert, C. Donahue, A. Moore, A. Ashkenazi (1996)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*The Journal of Biological Chemistry, 271
- Publisher
- Wiley
- Copyright
- Copyright © 1999 Wiley Subscription Services
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- DOI
- 10.1046/j.1365-2141.1999.01630.x
- Publisher site
- See Article on Publisher Site
Abstract
TRAIL is a potent death protein that favours the killing of various types of cancer cells to normal cells, but under the right conditions TRAIL can also kill activated human T cells. TRAIL mRNA is widely expressed by normal cells but its expression by primary tumour cells is not known. In this study, primary tumour cells of haemopoietic origin constitutively expressed TRAIL mRNA and protein and were capable of inducing the apoptosis of target Jurkat cells in a dose‐dependent manner. This killing effect was reversed by anti‐TRAIL antibody. The functional expression of TRAIL by lymphoid and myeloid malignant cells raises the possibility of its involvement in tumour cell evasion of immunosurveillance, and could be related to spontaneous tumour cell death and necrosis.
Journal
British Journal of Haematology – Wiley
Published: Jan 1, 1999
Keywords: ; ; ; ;